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Abstract
Objective. This study aims to provide robust estimates of EQ-5D as a function of the HAQ and pain in
patients with RA.
Method. Repeated observations were made of patients diagnosed with RA in a US observational cohort
(n= 100 398 observations) who provided data on HAQ, pain on a visual analogue scale and the EQ-5D ques-
tionnaire. We used a bespoke statistical method based on mixture modelling to appropriately reflect the
characteristics of the EQ-5D instrument and to compare this with results from standard multiple regression.
Results. EQ-5D can be predicted from summary HAQ and pain scores. We identify four different classes
of respondents who differ in terms of disease severity. Unlike the multiple regression, the mixture model
exhibits very good fit to the data and does not suffer from problems of bias or predict values outside the
feasible range.
Conclusion. It is appropriate to model the relationship between HAQ and EQ-5D but only if suitable
statistical methods are applied. Linear models underestimate the quality-adjusted life year benefits, and
therefore the cost-effectiveness, of therapies. The bespoke mixture model approach outlined here over-
comes this problem. The addition of pain as an explanatory variable greatly improves the estimates.
Reimbursement agencies rely on these types of analyses when formulating policy on the use of new
drug therapies. Clinicians as well as economists should be concerned with these issues.
Key words: rheumatoid arthritis, HAQ, pain, EQ-5D, health outcomes, quality of life, economic evaluation,
mapping.
Introduction
Economic evaluation of health care technologies is now a
technique in widespread use across most developed
health care systems and a key aid to decision makers. It
provides a rational framework to consider both the cost
and benefits of treatments that compete for scarce health
care resources. In RA, the advent of high-cost biologic
drugs has been a particular driver for the large number
of such cost-effectiveness analyses. In many jurisdictions,
decision makers wish to have health benefits of treat-
ments expressed in terms of quality-adjusted life years
(QALYs) so that comparisons across diverse disease
areas can be made using a common metric. The QALY
attaches weight to each year of survival to adjust for its
perceived quality. A year in full health is scored as 1 and
death is 0. These serve as the points around which all
intermediate health states are valued.
In order for the health benefits of a therapy to be esti-
mated in terms of QALYs gained, it is usual for an appro-
priate outcome measurement tool to be administered to
patients as part of the clinical trial. Several off-the-shelf
instruments are available, including the EQ-5D [1], SF-6D
[2] (a derivative of the SF-36) and the Health Utilities Index
[3]. Each of these instruments comprises questions that
ask patients to indicate their health on a range of dimen-
sions. Pre-existing scores on the QALY scale calculated
from the general populations of several different countries
are then available to attach to those health states.
However, in RA, many of the pivotal trials for new thera-
pies have failed to include such preference-based instru-
ments. In this situation, analysts have attempted to
estimate the relationship between clinical outcome meas-
ures that are included in trials (predominantly the HAQ)
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and preference-based measures via statistical modelling
[48]. These are almost all simple linear regression models,
which is problematic because this kind of statistical
model has been shown to fit badly to the data and
thereby undervalue treatment benefits. This is evident
from numerous studies in varying disease settings [9]
and in RA populations when using either the HAQ sum-
mary score [10] or the individual components of HAQ [4,
11] as predictors. In these cases, the statistical model
underestimates utility values for those patients with little
or no functional disability, but overestimates the utility
score for those with poor function.
This linking of clinical and economic outcome measures
has been referred to as mapping and has been subject
to substantial controversy. The OMERACT Economics
Group recognized this and reported that mapping
should be better explored [12]. Scott et al. [13] go so far
as to suggest that economic evaluations should not be
based on HAQ transformed to EQ-5D.
We have previously developed a new statistical ap-
proach to modelling EQ-5D [14]. Using a small dataset
from an early RA cohort, we demonstrated the appropri-
ateness of the method using HAQ and pain to estimate
EQ-5D scores. This article refines the method and applies
it to a much larger dataset to provide definitive results.
While this article concentrates on the UK EQ-5D tariff,
the issues are relevant to EQ-5D using scores from
other countries’ populations or for other health utility-
based instruments. Overall, we aim to estimate EQ-5D
as a function of HAQ and pain. The issue is not just of
importance to health economists but directly influences
the availability of drug and other therapies. In England
and Wales, for example, every single appraisal of biologic
therapies undertaken by the National Institute for Health
and Clinical Excellence (NICE) and their broader guide-
lines on the management of RA have relied in part on
estimating such a relationship.
Patients and methods
Data were provided by the US National Data Bank for
Rheumatic Diseases (NDB). The NDB is a not-for-profit
rheumatic disease research databank in which pa-
tients completed detailed self-report questionnaires at
6-month intervals [15]. Patients signed informed consent
forms before being enrolled in the NDB. The consent form
was approved by the Via Christie Institutional Review
Board. Eligible patients in this study were those with RA
who had completed a biannual survey for events occur-
ring between 1 July 2002 and 22 November 2010.
At each assessment, demographic variables were re-
corded, including sex, age, ethnic origin, education
level, current marital status, medical history and total
family income. Patients also complete the HAQ Disability
Index, including pain on a visual analogue scale (VAS)
scored from 0 to 100 and EQ-5D, amongst other items.
UK EQ-5D tariff values were used. Summary statistics for
the sample are provided in Table 1.
A total of 103 867 observations were included in the
total dataset from 16 011 patients; 3469 observations
had missing data and were not included in the statistical
models. The size of the dataset dwarfs that which is typ-
ical of most mapping studies. Patients spanned the full
range of HAQ, pain and EQ-5D values. Nevertheless,
very few observations were observed in the most extreme
HAQ health state. A total of 1244 observations (1.2%) from
528 patients had an HAQ exceeding 2.5, and just 152
observations (0.15%) from 64 patients had an HAQ of 3.
The histogram in Fig. 1 displays the key features typical
of EQ-5D. First, there is a substantial mass of observa-
tions at 1. There are 13 891 observations (14%) at full
health. Second, there is a gap between these observa-
tions and those for any level of impairment, as is imposed
by the method for calculating EQ-5D tariff scores. There
are then at least two more separate components to the
distribution with models around 0 and 0.75. There is a very
large mass of observations around 0.8. There are 50
observations in the so-called Pits state (i.e. 33333),
the worst state that can be described by the EQ-5D
descriptive system. These are the features of EQ-5D
that raise statistical challenges and result in the poor per-
formance of standard approaches.
Statistical methods
We aim to estimate the relationship between EQ-5D, HAQ
and pain on a scale of 0 to 100. Standard multiple regres-
sion models are in widespread use for modelling EQ-5D
but such models are rarely suitable when the distribution
of the variable of interest is complicated. It is clearly not
appropriate in this situation, given the bounded and multi-
modal nature of the distribution (Fig. 1), and has been
shown to perform poorly for this very reason. A linear
regression model was included here solely to confirm
this. Instead, we apply the general framework for estimat-
ing EQ-5D from Herna´ndez et al. [14], which combines
bespoke distributions in a mixture model. Full details are
provided elsewhere [14], however, the key details of the
two main elements of the approach are provided here.
First, mixture models are formed from a number of
different component distributions or classes that are
combined to form a new distribution: essentially, instead
of estimating a single statistical model, a mixture model is
based on simultaneously estimating as many separate
models (or classes) as the analyst requests. The overall
estimate of EQ-5D, predicted from any set of HAQ, pain
TABLE 1 Descriptive statistics of RA patients from NDB
by observation (n= 100 398)
Characteristic Value
Female, n (%) 79 639 (79.3)
RA duration (years) 17.17 (11.07)
Age (years) 62.82 (12.24)
Pain 35.32 (26.76)
HAQ 1.00 (0.73)
EQ-5D 0.66 (0.27)
All values are mean (S.D.) unless indicated oterwise.
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and age values, is a weighted function of these individual
components. The precise weights can also be based on
different explanatory variables. We chose this mixture ap-
proach because it offers an extremely flexible and con-
venient manner in which complex distributions (such as
EQ-5D) can be analysed [16]. So, while each of the indi-
vidual components can be based on standard statistical
assumptions, when these are combined together they can
form extremely non-standard distributions, as is clearly
required in this setting.
The analyst must exercise judgement in determining the
appropriate number of components. Adding an additional
component will always improve the extent to which the
model fits the actual data but it also loses generalizability.
We therefore used measures that compare models in
terms of fit but include a penalty for having more compo-
nents (Bayesian information criteria) as well as subjective
judgements as to whether adding an additional class cap-
tured a large or small amount of the data and whether this
was at the extremes of poor/good health, where even
small improvements can be particularly important. We
considered models that had between three and six sep-
arate components.
The second novel feature of the analysis is that, in this
case, instead of basing each separate class of the mixture
on a standard normal distribution, we based it instead on
a distribution specific to the characteristics of EQ-5D,
namely, limited above at full health (1), below at 0.594
and adjusted to reflect the gap in feasible values between
1 and 0.883.
Explanatory variables may enter the model in two ways:
either as predictors of the relationship with EQ-5D within
each of the individual classes, as in standard regression,
or as predictors of component membership. We com-
pared several different variants of using the explanatory
variables in these two ways and identified the best per-
forming approach.
Patients are followed every 6 months in the NDB.
Therefore each individual contributes multiple
assessments and these are likely to be correlated with
each other. All the models presented here reflect this cor-
relation using random effects terms. We compare the dif-
ferent statistical models using a number of different
measures that are commonly used to assess how well
the predictions from the model fit the actual data:
Akaike’s and Bayesian information criteria (AIC/BIC),
mean absolute error (MAE) and root mean squared
error (RMSE).
Many RA cost-effectiveness analyses are performed by
simulating many hypothetical, individual patients [7, 17].
By tracking these patients over a long time period, and
simulating their course of disease both with and without
the health technology that is the subject of the analysis, an
assessment of the difference in costs and benefits can be
made. In this situation, the cost-effectiveness analyst re-
quires our statistical models to estimate EQ-5D scores for
these individuals. This is different from the average EQ-5D
score. To reflect this use of the model results, we simu-
lated a set of 100 modelled EQ-5D scores for each of the
patients in the NDB dataset. This further illustrated differ-
ences between the observed data and the results gener-
ated by the linear regression and the mixture model
approaches.
Results
A four-class mixture model was selected as the optimal
model. Explanatory variables enter the model in two ways.
First, within each class, EQ-5D is predicted by HAQ and
HAQ2, pain, age and age2. Second, the probability of any
patient’s observation being in each of the four classes is
based on HAQ, pain and pain2. The optimal linear regres-
sion model included HAQ and HAQ2, pain, age and age2.
However, this model suffered very poor fit particularly at
the extremes of good health and poor health.
The mixture model vastly outperformed the linear model
in terms of summary fit measures. AIC and BIC were both
lower (indicating better fit) for the mixture model and there
was a 9.6% improvement in MAE and a 3.4% improve-
ment in RMSE. Importantly, the improvement in fit was
greatest at the extremes of very poor and very good
health. For those patients with an HAQ either between 0
and 1 or between 2 and 3, MAE improved by more than
11%. At pain scores of 0, the MAE reduces from 0.13 to
0.08, a 35% improvement. At pain scores exceeding 95,
the MAE reduces from 0.23 to 0.18, a 22% improvement.
These features are evident in Fig. 2, which plots the mean
EQ-5D versus (a) HAQ and (b) pain for the observed data,
the linear regression model and the preferred mixture
model. Results for this model are reported in Table 2.
The first class is by far the largest, with a mean prob-
ability of class membership of 0.73. In this class, HAQ and
pain are negatively related to EQ-5D (P= 0.000) (Table 2).
HAQ2 is not significant. A positive relationship with age
and age2 is demonstrated but in the case of age2 this is
not statistically significant (P= 0.230). The average char-
acteristics of those patients most likely to be in this class
are very similar to those of the average overall dataset.
Notably, these are less severely affected patients with a
FIG. 1 Distribution of EQ-5D scores from the NDB cohort.
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mean HAQ of approximately 1, EQ-5D of 0.67 and disease
duration of 17 years. Fig. 3a illustrates that this compo-
nent of the model has a peak around 0.7 that coincides
with that of the observed data in Fig. 1. This component
also contributes to the mass of data at EQ-5D equal to 1,
but does not contribute significantly to the lower end of
the distribution.
The mean probability of an observation being in the
second class is 0.05, making it the smallest class. This
component of the model has a large spread, including
both those patients in the most severe EQ-5D health
states and those in full health (Fig. 3b). The coefficients
on HAQ and HAQ2 indicate that EQ-5D decreases, by
increasing amounts, as HAQ worsens. The impact of
pain on EQ-5D in this group is the most pronounced of
all the classes. In those patients most likely to be assigned
to this group, the mean HAQ is almost 2.76 (S.D. 0.23),
EQ-5D is 0.33 (S.D. 0.32), but pain is relatively mild at
10.3 (S.D. 11.2). Patients most likely to be in this group
have an average RA duration in excess of 31 years.
Fig. 3c shows that the fourth component is centred
around EQ-5D of 0.2 and accounts in part for the
second element of the bi-modal EQ-5D distribution.
Seven per cent of patients are most likely to be assigned
to this component. HAQ is negatively associated with
EQ-5D and is much greater in magnitude than the positive
coefficient on HAQ2. Pain is also negatively associated
with EQ-5D. This is a class made up of patients with
poor functional status. The mean HAQ is 2.03 (S.D. 0.44).
These patients also have the most severe average pain
score for any of the four groups at 87.8 (S.D. 7.4).
The fourth class shows no statistically significant
relationship between EQ-5D and either age or pain. HAQ
is negatively related to EQ-5D (P< 0.05). HAQ2 is not
statistically significant. This group of 14% of the dataset
is made up of patients with mild or no symptoms.
The mean HAQ is 0.15 (S.D. 0.27), pain is 2.3 (S.D. 2.5)
and EQ-5D is 0.93 (S.D. 0.11). Fig. 3d illustrates how this
element of the model contributes predominantly to the
mass of values at EQ-5D equal to 1.
Fig. 3e shows that the key features of the EQ-5D data
distribution (Fig. 1) are replicated by the bespoke mixture
model: a mass of observations at 1, a gap to the next set
of feasible values, tri-modal and does not predict values
outside the feasible range either at the top or the bottom.
The linear regression model has none of these features
(Fig. 3f).
Discussion
Cost-effectiveness analyses of treatments for patients
with RA frequently estimate health benefits in terms of
QALYs by estimating the relationship between
preference-based outcome measures like EQ-5D and
clinical outcome measures like HAQ. However, the stat-
istical models used to do this tend to be relatively simplis-
tic and do not account for the many idiosyncrasies of the
EQ-5D instrument and valuation system. For this reason,
such approaches result in systematically biased estimates
that undervalue the benefits of treatments. Unsurpris-
ingly, this has led to criticism from the rheumatology
community since the methods used to estimate these
relationships are not merely of academic interest, but
form critical components of the analyses that reimburse-
ment authorities across the world rely on in reaching fund-
ing decisions [13]. These features are not limited to the UK
version of the EQ-5D and many are present in other qual-
ity-of-life instruments used to estimate QALYs such as the
SF-6D [2] and the Health Utilities Index [3]. Indeed, com-
parisons of linear models using several of these instru-
ments have been performed in RA using data from the
NDB [10].
This study uses a very large dataset to refine a flexible
statistical approach that was designed specifically to
address such shortcomings.
Results show that the preferred four-component model
does indeed overcome the problems of poor fit asso-
ciated with simplistic techniques. Fit is substantially
better at the extremes of the distribution and there is no
evidence of the systematic undervaluation of the benefits
FIG. 2 Mean observed and predicted values for linear and mixture models: (a) HAQ vs EQ-5D and (b) pain vs EQ-5D.
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of treatment. Where economic models estimate benefits
over a very long time period, these differences will have a
large additive effect year after year over a patient’s life-
time, which could be of critical importance in informing
policy makers. For example, many current estimates of
biologic therapies place them right at the boundary of
what decision makers consider to be cost effective.
Even marginal changes in the values that inform these
estimates are therefore going to be of direct importance
to clinicians and their patients.
Furthermore, the model is not capable of predicting
values that lie outside the feasible range (0.561 to 1).
Simple approaches generate such nonsensical estimates
particularly when they are used to simulate individual pa-
tients and when the parameter uncertainty in the esti-
mates is reflected in cost-effectiveness models. The
covariance matrix that would allow analysts to perform
such analyses with this model is available online
(Supplementary Data, available at Rheumatology Online).
Many cost-effectiveness analyses focus on changes in
HAQ due to treatment. This study demonstrates
that better estimates of the benefits of treatments in
terms of QALYs will be gained if HAQ and pain are
simultaneously considered. This is neither new [10, 14]
TABLE 2 Results from the four-class mixture model
Variable Parameter Robust S.E. t-value P-value
Explanatory variables within class 1 HAQ 0.0898 0.0027 32.9151 0.0000
HAQ2 0.0005 0.0009 0.5892 0.5557
Pain/100 0.0580 0.0023 25.4275 0.0000
Age/10m 0.0049 0.0005 10.1656 0.0000
Age/10m2 0.0003 0.0002 1.2111 0.2258
Explanatory variables within class 2 HAQ 0.0544 0.0301 1.8043 0.0712
HAQ2 0.0509 0.0100 5.1027 0.0000
Pain/100 0.3841 0.0225 17.0781 0.0000
Age/10m 0.0291 0.0035 8.2411 0.0000
Age/10m2 0.0023 0.0017 1.3532 0.1760
Explanatory variables within class 3 HAQ 0.1415 0.0076 18.5781 0.0000
HAQ2 0.0155 0.0027 5.7871 0.0000
Pain/100 0.0839 0.0089 9.3978 0.0000
Age/10m 0.0037 0.0012 3.2078 0.0013
Age/10m2 0.0007 0.0006 1.1702 0.2419
Explanatory variables within class 4 HAQ 0.1958 0.0811 2.4137 0.0158
HAQ2 0.0347 0.0246 1.4097 0.1586
Pain/100 0.0127 0.0693 0.1839 0.8541
Age/10m 0.0043 0.0058 0.7417 0.4583
Age/10m2 0.0002 0.0021 0.1106 0.9119
Variances for each class Variance 1 0.0025 0.0001 48.7842 0.0000
Variance 2 0.0240 0.0016 14.8595 0.0000
Variance 3 0.0022 0.0002 10.2405 0.0000
Variance 4 0.0044 0.0042 1.0374 0.2995
Random effects terms Intercept 1 0.8141 0.0013 629.4830 0.0000
Intercept 2 0.4266 0.0164 25.9934 0.0000
Intercept 3 0.3297 0.0081 40.6365 0.0000
Intercept 4 1.0220 0.0327 31.2430 0.0000
Male 0.0265 0.0013 20.9092 0.0000
Random effects Variance 0.0026 0.0001 46.2489 0.0000
Explanatory variables explaining the probability
of class membershipa
Intercept 1 1.2746 0.0637 20.0245 0.0000
HAQ 0.2420 0.4424 0.5471 0.5843
Pain/100 23.4673 0.5897 39.7970 0.0000
Pain/1002 21.5513 0.6707 32.1307 0.0000
Intercept 2 6.6310 0.2597 25.5366 0.0000
HAQ 2.1936 0.4234 5.1808 0.0000
Pain/100 18.3719 1.2220 15.0337 0.0000
Pain/1002 13.8001 0.8071 17.0981 0.0000
Intercept 3 7.4768 0.2988 25.0242 0.0000
HAQ 1.0517 0.4344 2.4209 0.0155
Pain/100 25.3396 1.1359 22.3075 0.0000
Pain/1002 16.9622 0.7624 22.2473 0.0000
aThese probabilities are computed using class 4 as the reference.
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nor surprising when one considers that pain is one of the
five domains in the EQ-5D instrument and contributes the
greatest weight to the summary score. Yet this finding
implies that economists will need to consider the
decision models they use and how meta-analysis
methods can capture treatment benefits appropriately.
The mixture model approach that has been reported
here was implemented because it offers a flexible frame-
work for complex distributions like EQ-5D. However, it
also opens the potential for the consideration of patient
subgroups: the relationship between HAQ and pain to
EQ-5D is very different within the four components of
the model. In some instances, pain is particularly import-
ant and in others it is HAQ that is critical. The patients who
are likely to form these groups are also very different in
terms of age, duration and severity of disease. These im-
plications require further investigation. It is also worth
noting that in the previous implementation of this model-
ling approach in RA, the preferred model comprised three
components. The addition of a fourth class here improved
fit at the bottom end of the EQ-5D distribution. Data at
this extreme of poor health were lacking in the study
by Herna´ndez et al. [14]. This issue is diminished but
not eliminated by using the NDB. The only place where
the mixture model does not fit extremely well is where
the HAQ exceeds 2.5. While a better model fit would
be achieved by fitting a greater number of classes to
the mixture, this would be at the expense of generalizabil-
ity. The validity of observations from patients at such
extreme levels of functional impairment may also be ques-
tionable and for this reason we propose the four-class
model.
More recent clinical trials of newer biologic agents are
increasingly incorporating preference-based outcome
measures. However, while it has often been claimed that
direct health utility assessment is preferable to using in-
direct mapping methods [4, 9], this is not necessarily the
case. Here we have a dataset comprising in excess of
100 000 observations across the full spectrum of func-
tional disability and pain combined with an appropriate
method to relate these measures to EQ-5D. On the
other hand, clinical studies, particularly trials, have limited
patient variability and follow-up. Economic evaluations
therefore extrapolate well beyond these clinical studies,
often over the entire patient lifetime, to accurately capture
the impact of treatment on long-term costs and health
benefits. Our approach offers a means by which such ex-
trapolations can be undertaken.
Furthermore, even if new trials include measures like
EQ-5D, the entirety of the evidence base remains relevant,
including studies of older treatments as comparators.
Hence, given that such estimates will be critical to
reimbursement decisions for some time to come, it is
of vital importance for patients and their physicians
that treatment benefits are appropriately valued. The
results reported here can be used in future economic
evaluations.
Rheumatology key messages
. Economic evaluations in RA often estimate EQ-5D
treatment benefits indirectly from measures such as
HAQ.
. Standard methods underestimate RA treatment
benefits while the bespoke statistical method pre-
sented here does not.
. In RA, QALYs should be estimated from HAQ and
pain using statistical methods presented here.
FIG. 3 Distribution of simulated values from the four-component mixture and linear models: (a)(d) for each component
individually, (e) four-class combined and (f) linear model.
www.rheumatology.oxfordjournals.org 949
Relationship between EQ-5D, HAQ and pain
Disclosure statement: The authors have declared no con-
flicts of interest.
Supplementary data
Supplementary data are available at Rheumatology
Online.
References
1 EuroQol Group. EuroQol—a new facility for the measure-
ment of health-related quality of life. Health Policy 1990;
16:199208.
2 Brazier J, Roberts J, Deverill M. The estimation of a
preference-based measure of health from the SF-36.
J Health Econ 2002;21:27192.
3 Torrance G, Feeny D, Furlong W et al. Multiattribute utility
function for a comprehensive health status classification
system. Health Utilities Index Mark 2. Med Care 1996;34:
70222.
4 Bansback NJ, Marra C, Tsuchiya A et al. Using the health
assessment questionnaire to estimate preference-based
single indices in patients with rheumatoid arthritis. Arthritis
Rheum 2007;57:96371.
5 Marra CA, Marion SA, Guh DP et al. Not all ‘quality ad-
justed life years’ are equal. J Clin Epidemiol 2007;60:
61624.
6 Lindgren P, Geborek P, Kobelt G. Modeling the
cost-effectiveness of treatment of rheumatoid arthritis with
rituximab using registry data from southern Sweden. Int
J Technol Assess 2009;25:1819.
7 Wailoo AJ, Bansback N, Brennan A et al. Biologic drugs
for rheumatoid arthritis in the Medicare program: a cost
effectiveness analysis. Arthritis Rheum 2008;58:93946.
8 Hurst NP, Kind P, Ruta D et al. Measuring health related
quality of life in rheumatoid arthritis: validity, responsive-
ness and reliability of EuroQol. Br J Rheumatol 1997;36:
5519.
9 Brazier J, Yang Y, Tsuchiya A et al. A review of studies
mapping (or cross walking) non-preference based meas-
ures of health to generic preference-based measures. Eur
J Health Econ 2010;11:21525.
10 Wolfe F, Michaud K, Wallenstein G. Scale characteristics
and mapping accuracy of the US EQ-5D, UK EQ-5D, and
SF-6D in patients with rheumatoid arthritis. J Rheumatol
2010;37:1615.
11 Harrison M, Lunt M, Verstappen SMM et al. Exploring
the validity of estimating EQ-5D and SF-6D utility values
from the health assessment questionnaire in patients
with inflammatory arthritis. Health Qual Life Outcomes
2010;8:21.
12 Harrison MJ, Bansback N, Marra C et al. Valuing
health for clinical and economic decisions: directions
relevant for rheumatologists. J Rheumatol 2011;38:
17705.
13 Scott DL, Khoshaba B, Choy EH et al. Limited correlation
between the Health Assessment Questionnaire (HAQ) and
EuroQoL in rheumatoid arthritis: questionable validity of
deriving quality adjusted life years from HAQ. Ann Rheum
Dis 2007;66:15347.
14 Herna´ndez Alava M, Wailoo AJ, Ara R. Tails from the peak
district: adjusted limited dependent variable mixture
models of EQ-5D health state utility values. Value Health
2012;15:55061.
15 Wolfe F, Michaud K. The National Data Bank for rheumatic
diseases: a multi-registry rheumatic disease data bank.
Rheumatology 2011;50:1624.
16 McLachlan GJ, Peel D. Finite mixture models. New York:
Wiley, 2000.
17 Chen Y-F, Jobanputra P, Barton P et al. A systematic
review of the effectiveness of adalimumab, etanercept
and infliximab for the treatment of rheumatoid arthritis
in adults and an economic evaluation of their
cost-effectiveness. Health Technol Assess 2006;10:iiiiv,
xixiii, 1229.
950 www.rheumatology.oxfordjournals.org
Mo´nica Herna´ndez Alava et al.
